Results 191 to 200 of about 659,302 (281)

Adjunctive Cold Atmospheric Plasma Therapy for Tracheostomy Wound Healing in Critically Ill Patients: A Pilot Randomised Controlled Trial

open access: yesInternational Wound Journal, Volume 23, Issue 10, October 2026.
ABSTRACT Cold atmospheric plasma (CAP) therapy has emerged as a promising therapy for wound healing. This study aimed to evaluate the feasibility, safety and efficacy of adjunctive CAP therapy for early tracheostomy wound healing compared with standard wound care (SWC) alone.
Lalita Jaingim   +3 more
wiley   +1 more source

Use of a Synthetic Polylactic Acid Matrix for Pyoderma Gangrenosum: A Case Series

open access: yesInternational Wound Journal, Volume 23, Issue 10, October 2026.
ABSTRACT Pyoderma gangrenosum (PG) is a rare chronic neutrophilic dermatosis closely associated with immune dysregulation and characterized by painful, treatment‐resistant ulcers. Currently, no standardized therapeutic protocol exists; however, topical and systemic immune‐modulating therapies have shown positive results.
José Luis Ramírez‐García‐Luna   +5 more
wiley   +1 more source

Prevention of diabetic foot ulcer.

open access: yesInternational journal of preventive medicine, 2013
Bijan Iraj   +3 more
openaire   +2 more sources

A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People With Diabetes: A Randomized Controlled Trial

open access: yesInternational Wound Journal, Volume 23, Issue 10, October 2026.
ABSTRACT Diabetic foot ulcers (DFUs) are a devastating complication of diabetes that markedly affects quality of life and generates significant socioeconomic and healthcare burdens. When DFUs fail to respond to standard of care (SOC), advanced therapies including Cellular, Acellular and Matrix‐like Products (CAMPs) are often employed. A novel composite
David G. Armstrong   +9 more
wiley   +1 more source

Metabolomic profiling and vitamin D pathway investigation in diabetic foot ulcer patients. [PDF]

open access: yesMetabolomics
Reveendran R   +5 more
europepmc   +1 more source

A Prospective Cohort Study of Hard‐to‐Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add‐on to Optimal Local Care

open access: yesInternational Wound Journal, Volume 23, Issue 10, October 2026.
ABSTRACT ReGenerating Tissue Agents (RGTA, trade name CACIPLIQ20) contain a structural analogue of heparan sulfates (HSs) that promotes tissue regeneration in hard‐to‐heal chronic wounds resistant to the best standard of care for 6 months or longer.
Serge Ynesta   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy